Get started
Author

P.I.E.T. Ost

Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration
2026 · Chad Tang, Alex D Sherry, et al. · The Lancet Oncology · 29
Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 Trial
2026 · Pirus Ghadjar, Stefanie Hayoz, et al. · European Urology · 5
Reducing adverse effects in hypofractionated radiotherapy for prostate cancer: Clinical evidence and emerging mitigation strategies
2025 · Jennifer Le Guevelou, Thomas Zilli, et al. · Prostate Cancer and Prostatic Diseases · 4
ESTRO’s principles for environmental sustainability in the radiation oncology community
2026 · Kari Tanderup, Anna M. Kirby, et al. · Radiotherapy and Oncology · 2
Health-related Quality of Life Outcomes of Salvage Metastasis-directed Treatment Versus Elective Nodal Treatment for Oligorecurrent Nodal Prostate Cancer: A Secondary Analysis of the Phase 2, Open-label PEACE V–STORM Randomized Trial
2026 · Thomas Zilli, Shankar Siva, et al. · European Urology Oncology · 1
PDF
ESTRO's principles for environmental sustainability in the radiation oncology community.
2026 · Tanderup, Kari, Kirby, Anna M, et al. · Open Access CRIS of the University of Bern
Multifocal cohort analysis unveils cell types associated with regional lymph node seeding in prostate cancer
2026 · Louise de Schaetzen van Brienen, Taewoo Jung, et al. · Genome Medicine
Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 Trial.
2026 · Ghadjar, Pirus, Hayoz, Stefanie, et al. · Open Access CRIS of the University of Bern
A clinical, evidence-based risk estimator for individualizing benefit and response in oligometastatic prostate cancer (CEREBRO): A tool from the X-Met collaboration.
2026 · Alexander Dean Sherry, Piet Ost, et al. · Journal of Clinical Oncology
Opening the black box: Biologic pathways underlying multimodal digital-pathology artificial intelligence in metastatic prostate cancer.
2026 · Amol C. Shetty, Yang Song, et al. · Journal of Clinical Oncology
SAVE: A multicenter randomized phase 2 trial of salvage radiotherapy (SRT) with androgen-deprivation therapy (ADT) versus apalutamide (Apa) for biochemical progression after radical prostatectomy (RP).
2026 · Piet Dirix, Peter Schatteman, et al. · Journal of Clinical Oncology
PDF
Phase III, randomized, double-blind, placebo-controlled study of adjuvant saruparib (AZD5305) in patients with BRCAm localized high-risk prostate cancer who are receiving radiotherapy and androgen deprivation therapy (EvoPAR-Prostate02).
2026 · Rana R. McKay, Wassim Abida, et al. · Journal of Clinical Oncology
Re: Riccardo Bertolo, Antonio Luigi Pastore, Paolo Verze, et al. Real-World Burden and Management of Late Genitourinary Toxicity After Prostate Radiotherapy: Insights from IRRADIaTE, the Italian Registry of Radiotherapy-Associated Disorders and Urological Treatment & Evaluation. Eur Urol Oncol. 2026;9:408–416. https://doi.org/10.1016/j.euo.2026.01.005
2026 · Alfonso Gomez-Iturriaga, Paul Sargos, et al. · European Urology Oncology
Health-related Quality of Life Outcomes of Salvage Metastasis-directed Treatment Versus Elective Nodal Treatment for Oligorecurrent Nodal Prostate Cancer: A Secondary Analysis of the Phase 2, Open-label PEACE V-STORM Randomized Trial.
2026 · Zilli, Thomas, Siva, Shankar, et al. · Open Access CRIS of the University of Bern
Automated evaluation of organ sparing in prostate stereotactic body radiation therapy using dose-gradient metrics
2026 · Geert De Kerf, Michaël Claessens, et al. · Physics and Imaging in Radiation Oncology
PDF
SP-0021: Should oligometastatic disease in prostate cancer be treated systemically?: the radiation oncologist point of view
2014 · G. De Meerleer, T.O.M. Claeys, et al. · Radiotherapy and Oncology
Works count: 16
Citation count: 40
H-index: 3
I10-index: 1
Year
Topic
Type